CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 130 enrolled
Drug / intervention
Standard Careother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01254318
NCT01254318N/ACompleted
CompareCT.gov

Temporal Realistic Assessment of the Fungal Infection Incidence Across Canada for High Risk Subjects With Hematological Disease (TRAFIC)

Merck Sharp & Dohme LLC·observational·Posted Dec 6, 2010·Updated Nov 2, 2016

In Brief

An observational study evaluating Standard Care for Mycoses and Leukemia. Completed, enrolled 130 participants.

Detailed Summary

This will be a retrospective study that includes retrospective chart reviews at major institutions across Canada. The intent of the study is to generate both regional and national incidence data for non-Candida invasive fungal infections (IFI) in high risk participants. The study will include participants receiving stem cell transplant and high dose chemotherapy treatment for leukemia.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMycoses, Leukemia
Countries--
CollaboratorsMcGill University Health Centre/Research Institute of the McGill University Health Centre

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 6, 2010
Enrollment StartMar 1, 2013
Primary CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 15.6 years ago

Interventions

Standard Careother

Health-care interventions will be recorded; no additional procedures outside the standard of care will be required.